Bioapp

About Bioapp

BioApplications Inc., established in 2011 and headquartered in Pohang, South Korea, operates at the forefront of the biotechnology industry, specializing in plant-based molecular farming. The company leverages a proprietary technology platform to manufacture biopharmaceuticals, positioning itself as a cost-effective and safer alternative to conventional mammalian cell-based production methods. This core technology underpins the development of animal vaccines and high-value recombinant proteins, catering to the global push for sustainable and efficient biomanufacturing. The company's vision is guided by its CEO, Dr. Eun-Ju Sohn, whose extensive research background in plant-made recombinant proteins and vaccines at institutions like the Pohang University of Science and Technology forms the scientific bedrock of the company's innovations.

The company's business model is centered on the development and commercialization of its proprietary products. Revenue is generated through the sale of these biopharmaceuticals to agricultural and life science sectors. A significant milestone was the raising of $3.9 million in a Series A funding round in July 2022, with notable investors including POSCO, BNK Venture Capital, and Wonik Investment Partners, signaling strong market confidence in its platform. This financial backing supports the company's expansion and R&D efforts. Strategic partnerships are key to its global strategy, highlighted by a collaboration with Canada's PlantForm Corp. and POSCO International to license and distribute its flagship vaccine in the Americas and other international markets.

BioApplications offers two primary product lines. The first is HERBAVAC™, the world's first commercialized plant-based green marker vaccine. Specifically, HERBAVAC™ CSF is designed to combat Classical Swine Fever (CSF), a highly contagious and economically damaging viral disease in pigs. A key feature of this subunit vaccine is a unique marker that allows veterinarians to differentiate between vaccinated and infected animals, a critical factor for disease control and international trade. The second major product brand is GLEAP™, which specializes in recombinant proteins. These proteins have diverse applications, serving as growth factors for the cultured meat industry, components for diagnostic antigens, and active ingredients in cosmetics, demonstrating the versatility of the company's production platform.